Literature DB >> 10155295

Necessity of using intermediate outcome to proxy long term effects. The example of thrombolytics.

J S Schwartz1.   

Abstract

Mesh：

Substances：

Year:  1995        PMID： 10155295     DOI： 10.2165/00019053-199507010-00002

Source DB:  PubMed          Journal:  Pharmacoeconomics        ISSN： 1170-7690            Impact factor:   4.981


× No keyword cloud information.
  22 in total

1.  Presenting economic information for decision making.

Authors:  A Pelc
Journal:  Pharmacoeconomics       Date:  1994-10       Impact factor: 4.981

2.  The journal's policy on cost-effectiveness analyses.

Authors:  J P Kassirer; M Angell
Journal:  N Engl J Med       Date:  1994-09-08       Impact factor: 91.245

3.  Trial of tissue plasminogen activator for mortality reduction in acute myocardial infarction. Anglo-Scandinavian Study of Early Thrombolysis (ASSET).

Authors:  R G Wilcox; G von der Lippe; C G Olsson; G Jensen; A M Skene; J R Hampton
Journal:  Lancet       Date:  1988-09-03       Impact factor: 79.321

4.  The impact of pharmacoeconomics on the practitioner and the patient: a conflict of interests?

Authors:  P Davey; M Malek
Journal:  Pharmacoeconomics       Date:  1994-10       Impact factor: 4.981

5.  Preexisting cardiovascular conditions and long-term prognosis after initial myocardial infarction: the Framingham Study.

Authors:  L A Cupples; D R Gagnon; N D Wong; A M Ostfeld; W B Kannel
Journal:  Am Heart J       Date:  1993-03       Impact factor: 4.749

6.  Intravenous tissue plasminogen activator and size of infarct, left ventricular function, and survival in acute myocardial infarction.

Authors:  F Van de Werf; A E Arnold
Journal:  BMJ       Date:  1988-11-26

7.  A reappraisal of hepatitis B virus vaccination strategies using cost-effectiveness analysis.

Authors:  B S Bloom; A L Hillman; A M Fendrick; J S Schwartz
Journal:  Ann Intern Med       Date:  1993-02-15       Impact factor: 25.391

8.  In-hospital mortality and clinical course of 20,891 patients with suspected acute myocardial infarction randomised between alteplase and streptokinase with or without heparin. The International Study Group.

Authors: 
Journal:  Lancet       Date:  1990-07-14       Impact factor: 79.321

9.  GISSI-2: a factorial randomised trial of alteplase versus streptokinase and heparin versus no heparin among 12,490 patients with acute myocardial infarction. Gruppo Italiano per lo Studio della Sopravvivenza nell'Infarto Miocardico.

Authors: 
Journal:  Lancet       Date:  1990-07-14       Impact factor: 79.321

Review 10.  Streptokinase. A review of its pharmacology and therapeutic efficacy in acute myocardial infarction in older patients.

Authors:  P E Battershill; P Benfield; K L Goa
Journal:  Drugs Aging       Date:  1994-01       Impact factor: 3.923
View more
  1 in total

Review 1.  Streptokinase. A pharmacoeconomic appraisal of its use in the management of acute myocardial infarction.

Authors:  J C Gillis; K L Goa
Journal:  Pharmacoeconomics       Date:  1996-09       Impact factor: 4.981
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.